BidaskClub Lowers Mylan (MYL) to Sell

BidaskClub lowered shares of Mylan (NASDAQ:MYL) from a hold rating to a sell rating in a research note issued to investors on Monday, BidAskClub reports.

Several other brokerages also recently issued reports on MYL. Mizuho reiterated a neutral rating on shares of Mylan in a research report on Thursday, January 31st. Wells Fargo & Co reduced their price target on shares of Mylan from $40.00 to $33.00 and set an outperform rating on the stock in a research report on Wednesday, February 27th. BMO Capital Markets upped their price target on shares of Mylan to $40.00 and gave the stock an outperform rating in a research report on Wednesday, February 27th. They noted that the move was a valuation call. Sanford C. Bernstein downgraded shares of Mylan from an outperform rating to a market perform rating and set a $33.00 price target on the stock. in a research report on Wednesday, February 27th. Finally, BTIG Research cut their target price on shares of Mylan to $35.00 and set a buy rating on the stock in a research report on Wednesday, February 27th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the company. The company currently has an average rating of Buy and an average target price of $37.35.

Shares of NASDAQ MYL opened at $19.17 on Monday. The stock has a market cap of $10.14 billion, a P/E ratio of 4.19, a P/E/G ratio of 1.02 and a beta of 1.44. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.85 and a current ratio of 1.51. Mylan has a 12-month low of $18.93 and a 12-month high of $42.50.

Mylan (NASDAQ:MYL) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $0.82 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.79 by $0.03. The business had revenue of $2.50 billion for the quarter, compared to the consensus estimate of $2.70 billion. Mylan had a net margin of 2.14% and a return on equity of 18.96%. The firm’s quarterly revenue was down 7.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.96 EPS. On average, sell-side analysts forecast that Mylan will post 4.28 earnings per share for the current fiscal year.

In other Mylan news, insider Paul Campbell sold 11,533 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $27.50, for a total transaction of $317,157.50. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.81% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. increased its stake in shares of Mylan by 2.6% in the 4th quarter. BlackRock Inc. now owns 39,965,771 shares of the company’s stock valued at $1,095,061,000 after acquiring an additional 1,018,811 shares during the last quarter. Vanguard Group Inc increased its stake in shares of Mylan by 1.4% in the 3rd quarter. Vanguard Group Inc now owns 35,774,112 shares of the company’s stock valued at $1,309,333,000 after acquiring an additional 506,649 shares during the last quarter. Pzena Investment Management LLC increased its stake in shares of Mylan by 0.3% in the 1st quarter. Pzena Investment Management LLC now owns 21,027,676 shares of the company’s stock valued at $595,924,000 after acquiring an additional 71,010 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of Mylan by 46.1% in the 1st quarter. AQR Capital Management LLC now owns 10,136,218 shares of the company’s stock valued at $287,261,000 after acquiring an additional 3,198,028 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Mylan by 4.9% in the 1st quarter. Geode Capital Management LLC now owns 8,264,693 shares of the company’s stock valued at $233,863,000 after acquiring an additional 389,489 shares during the last quarter. Institutional investors own 82.73% of the company’s stock.

Mylan Company Profile

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.

Featured Article: What is the Rule of 72?

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.